RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.
Stocks · News reference
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.
Law firm Lowey Dannenberg is investigating Aardvark Therapeutics for potential federal securities violations related to its lead drug ARD-101. The company paused its Phase 3 trial in February 2026 due to cardiac safety concerns and faced an FDA clinical hold in May 2026, causing significant stock price declines and shareholder losses.
Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.